CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 2,367	$ 1,799	$ 6,511	$ 5,039
General and administrative	2,125	2,385	6,312	7,523
Total operating expenses and operating loss	(4,492)	(4,184)	(12,823)	(12,562)
Non-operating income (expense), net:
Change in fair value of warrant liability	6	(49)	25	1,108
Change in fair value of contingent consideration	13	(28)	(268)	(510)
Interest income, net	0	59	25	91
Total non-operating income (expense), net	19	(18)	(218)	689
Net loss	(4,473)	(4,202)	(13,041)	(11,873)
Deemed dividend arising from warrant modifications	0	(7,268)	(78)	(8,659)
Net loss attributable to common stockholders	$ (4,473)	$ (11,470)	$ (13,119)	$ (20,532)
Per share information:
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.53)	$ (2.68)	$ (1.83)	$ (11.37)
Weighted-average common shares outstanding, basic and diluted (in shares)	8,418,038	4,281,855	7,174,859	1,805,773